Lack of transparency hampers cancer drug debate


19 August 2019 - The current debate raging over cancer drug funding is emotional, and the different agenda of lobby groups and pharmaceutical companies are often glossed over or lost.

Those on both sides of the great drug funding debate say the other needs to be more transparent in their agenda and their processes. 

They’re both right.

Read Newsroom article

Michael Wonder

Posted by:

Michael Wonder